The Kidney Health newsletter covers screening for & monitoring of CKD, discussion of medications to slow the progression of CKD, considerations for adding these medications, and additional CKD related FAQs.
Kidney Health - Frequently Asked Questions
Four frequently asked questions covering the prevention of kidney disease progression management e.g. how and when to add medication, blood pressure and A1c targets, and what (if any) role tirzepatide has in this population.
This clinician-facing tool highlights the available evidence on SGLT2 inhibitor adverse events. The infographic provides a concise summary of key data, while full evidence tables with references are available in the online extras.
This clinician-facing tool highlights the available evidence on GLP1 agonist adverse events. The infographic provides a concise summary of key data, while full evidence tables with references are available in the online extras.
Sick Day Management
This patient-friendly tool offers guidance on safely pausing certain medications during illness and dehydration. It includes tips on recognizing dehydration, identifies which medications to hold, provides tailored reminders for individuals with diabetes or heart failure, and reminds patients to restart medications when feeling well again.
Physical Activity Prescription
The Physical Activity Prescription highlights the importance of regular exercise, offering practical examples and guidelines to help patients and healthcare professionals work together to integrate exercise into daily routines. This resource provides valuable tips and recommendations for both aerobic and strength activities, designed to help individuals gradually enhance their physical function and overall health. It also underscores the numerous health benefits of physical activity, including reducing the risk of chronic diseases, improving quality of life, and managing pain.
The Renal Insufficiency in Older Adults chart highlights key considerations in managing CKD in older adults. It covers kidney function and risk assessment, management of comorbidities and adverse drug events, drug dose adjustments, and special considerations when estimating renal elimination.
Diabetes and the Kidneys
This chart highlights key strategies for protecting and preserving kidney function. It covers prevention of acute kidney injury, minimizing medication-related adverse events, and supporting the maintenance of existing renal function.
EMPA-KIDNEY Trial Summary
The EMPA-KIDNEY trial examines empagliflozin to prevent the progression of kidney disease in those with or without Type 2 Diabetes.
DAPA-CKD Trial Summary
The DAPA-CKD trial examines dapagliflozin to prevent the progression of kidney disease in those with or without Type 2 Diabetes.
CREDENCE Trial Summary
The CREDENCE trial examines canagliflozin to prevent the progression of kidney disease in those with Type 2 Diabetes.
FLOW Trial Summary
The FLOW trial examines semaglutide to prevent the progression of kidney disease in those with Type 2 Diabetes.
FIDELIO-DKD Trial Summary
The FIDELIO-DKD trial examines finerenone to prevent the progression of kidney disease in those with Type 2 Diabetes and moderate-severely elevated albuminuria.
FIGARO-DKD Trial Summary
The FIGARO-DKD trial examines finerenone in reducing cardiovascular mortality and morbidity in those with Type 2 Diabetes and moderate-severely elevated albuminuria.
FIDELITY Pooled Analysis
FIDELITY is a pooled efficacy and safety analysis of results from FIDELIO-DKD and FIGARO-DKD trials.
CONFIDENCE Trial Summary
The CONFIDENCE trial examines the simultaneous initiations of finerenone and empagliflozin on urine albumin-creatinine-ratio in those with CKD and Type 2 Diabetes.